Key facts
- This page summarizes Robert A. Lenz's Form 4 filing for Neumora Therapeutics, Inc. (NMRA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 Feb 2025, 17:12.
Robert A. Lenz - 18 Feb 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)
- Reporting relationship
- Head of R&D
- Issuer ticker
- NMRA
- Reported as of
- 18 Feb 2025
- Net transaction value
- -$9,383
- SEC form
- 4
- Accepted by SEC
- 20 Feb 2025, 17:12:34 UTC
- Prior SEC filing
- 18 Feb 2025
- Next SEC filing
- 10 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Milligan, as Attorney-in-Fact for Robert A. Lenz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert A. Lenz filed Form 4 for Neumora Therapeutics, Inc. (NMRA) on 20 Feb 2025.
Change
- Previous filing in this sequence was filed on 18 Feb 2025.
- Current net transaction value: -$9,383.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NMRA
transaction
Common Stock
Sale
- Transaction value
- $9,383
- Shares
- -5,614
- Change %
- -1.8%
- Price
- $1.67
- Shares after
- 309,092
- Date
- 18 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on June 12, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.
Footnote F2
This transaction was executed in multiple trades in prices ranging from $1.66 to $1.695, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.